

# Development of new drug Vonifimod for the treatment of Alopecia Areata

NEXTGEN Bioscience



OTHERS	Phase 2
Product Type	Small molecule
Indication	1 <sup>st</sup> indication : Alopecia Areata 2 <sup>nd</sup> indication : Ulcerative colitis
Target	Sphingosine-1-phosphate receptor (S1PR) 1 and 4
MoA(Mechanism of Action)	The functional antagonist of S1PR1 & 4 Vonifimod affects lymphocyte trafficking which leads to immune suppression
Competitiveness	<ol style="list-style-type: none"> <li>1. Selective towards S1P receptor subtypes associated with lymphocyte</li> <li>2. Absence of off-target safety risk; No significant CV events or macular edema</li> <li>3. Reduced risk of opportunistic infections due to relatively shorter half-life</li> <li>4. No titration required</li> <li>5. Rapid suppression of lymphocytes &amp; recovery</li> </ol>
Development Stage	Phase 2
Route of Administration	Oral Administration